CC BY-NC-ND 4.0 · South Asian J Cancer 2021; 10(03): 187-189
DOI: 10.1055/s-0041-1736032
Original Article: Skin Cancer

Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience

1  Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India
,
Joydeep Ghosh
1  Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India
,
Deepak Mishra
2  Department of Molecular Pathology, Tata Medical Center, Kolkata, West Bengal, India
,
Gautam Biswas
3  Department of Plastic Surgery, Tata Medical Center, Kolkata, West Bengal, India
,
Deepak Dabkara
1  Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India
,
Somanth Roy
1  Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India
,
Bivas Biswas
1  Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India
› Author Affiliations

Abstract

Background Combination of dabrafenib–trametinib is one of the standard treatments in patients with BRAF-mutated advanced malignant melanoma (MM). Real-world data on the usage of this combination is scarce, especially from India. Here, we are reporting our early experience with the usage of this combination therapy.

Materials and Methods This is a single institutional data assessment of patients with BRAF-mutated MM registered and treated with BRAF–MEK inhibitors in our hospital. Clinico-pathological features and treatment details were reviewed for all patients.

Results A total of seven patients with BRAF-mutated MM treated with this combination therapy with a median age of 66.5 years (range: 49–72 years) and a male:female ratio of 3:4. Six (85.7%) patients had metastatic disease at presentation. In total, 80% of our patient population had two or less than two sites of metastasis at presentation. The initial response rate of the study population was 71%. The drug was well tolerated with fever being the most common side effect which was seen in two (28.5%) of the patients.

Conclusion Combination of dabrafenib–trametinib is effective in patients with BRAF-mutated MM with good tolerability. Further studies are required to look for improvement in outcome in this group of patients.



Publication History

Publication Date:
24 November 2021 (online)

© 2021. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd
A-12, Second Floor, Sector -2, NOIDA -201301, India